What happens to your weight when you stop a GLP-1

Why everyone asks this eventually

Almost everyone on a GLP-1 lands on the same question sooner or later. You hit the goal you set. Or the prescription gets too expensive, or your plan stops covering it, or the supply dries up for a few weeks. Or you are just tired of the weekly shot and the gut side effects that come with it. Whatever the trigger, the worry underneath is the same: if I stop, does the weight come straight back?

It is a fair thing to be nervous about, and the internet will hand you ten confident answers in five minutes. The useful place to look is the small set of trials that ran the actual experiment: put people on a GLP-1, get them to a lower weight, then deliberately take the drug away and watch what happens next.

What the withdrawal trials actually found

The clearest picture comes from the STEP 1 extension. In the main trial, people on semaglutide (the drug in Wegovy and Ozempic) lost about 17 percent of their body weight over 68 weeks. Then the drug stopped. A year later they had regained two-thirds of that loss, landing about 5.6 percent below where they started . So not all the way back, but most of the way.

A second semaglutide trial, STEP 4, caught the split in real time. Everyone spent 20 weeks on the drug and lost about 11 percent. Then half kept taking it and half quietly switched to a placebo. Over the next year the group that stayed on semaglutide lost roughly another 8 percent, while the placebo group gained back about 7 percent . Same people, same starting point, opposite directions, and the only difference was whether the drug was still in the picture.

Tirzepatide (the drug in Mounjaro and Zepbound) tells the same story. In SURMOUNT-4, people lost a striking 21 percent over 36 weeks before being split into continue or stop. Those who kept going lost a further 5.5 percent. Those switched to placebo regained about 14 percent over the next year . The newer, stronger drug does not change the pattern. It just makes the gap between staying on and coming off wider.

Why the weight comes back

This is not willpower collapsing the day you stop. It is about what the drug was doing in the first place. A GLP-1 copies a gut hormone that helps regulate appetite, and the FDA label for semaglutide puts it plainly: the drug lowers how many calories you eat, mostly by quieting appetite . While it is in your system, eating less feels easy because hunger is turned down. Take it away and the hunger turns back up, often along with the food noise that had gone quiet.

The bigger frame is that obesity behaves like a chronic condition, not a one-time problem you fix and walk away from. The same label describes these drugs as something you use to reduce weight and keep it off over the long term , and the STEP 1 researchers concluded bluntly that ongoing treatment is needed to hold onto the weight loss and the health improvements that came with it . The drug manages the condition. It does not cure it.

It is not all-or-nothing

Two things are true at once, and it helps to hold both. The weight does tend to come back, and most people do not end up all the way back at their starting line. In the STEP 1 extension, even a full year off the drug, the average person was still about 5.6 percent lighter than when they began . These are also averages, which means some people regain almost everything and some hold onto a good chunk. Your result is not the trial mean.

What the trials cannot tell you is how to stop and keep it all off, because that is not what they tested. They compared staying on the drug with coming off it, not clever ways to taper or the perfect maintenance routine. The honest state of the evidence is that there is no proven trick that turns a GLP-1 into a short course. The general habits that support any weight maintenance, enough protein, strength training, regular movement, are reasonable to lean on, but do not expect them to fully replace what the drug was doing. Anyone promising they will is selling something.

If you are thinking about stopping

People come off GLP-1s for real reasons: cost, side effects, hitting a goal, a pregnancy plan, a supply gap. None of that is a moral failing, and this is not a sermon about staying on forever. The point is simpler. If you stop, the trials say to expect appetite to return and the scale to drift up, so it is worth deciding in advance what you want to do about that instead of being blindsided three months later.

How to actually do it, whether to taper the dose, whether to switch products, what to watch for, is a conversation for the prescriber who knows your history, not a script from an article. And if a stalled plateau or rough side effects are what is pushing you toward quitting, those often have other fixes worth raising first.

The bottom line

Stopping a GLP-1 usually means giving back a large share of the weight, because the drug works by quieting appetite and that effect leaves when the drug does. The withdrawal trials are consistent on this for both semaglutide and tirzepatide, and they frame these as long-term medications rather than a short course. That is not a reason to never start, and it is not a reason to panic. It is just the real shape of the thing, worth knowing before you are standing at the decision.

For research and educational purposes only. Not medical advice.

A note on how this was put together: pepSmart has not commissioned independent clinical review of this article, and every figure above is pulled straight from the trial papers and the FDA label, not from memory. You can read more about our editorial process and contributors and our sourcing posture, and if you spot an error, email a correction.

Sources: 4 entries, all primary canon (the FDA prescribing information for semaglutide and three peer-reviewed withdrawal trials, two in JAMA and one in Diabetes, Obesity and Metabolism), last reviewed 2026-06-11.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• GLP-1 taper planner overview - Public overview of the Pro GLP-1 taper planner.